New York State Common Retirement Fund Purchases 20,311 Shares of Annexon, Inc. (NASDAQ:ANNX)

New York State Common Retirement Fund raised its position in shares of Annexon, Inc. (NASDAQ:ANNX) by 143.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,479 shares of the company’s stock after purchasing an additional 20,311 shares during the period. New York State Common Retirement Fund’s holdings in Annexon were worth $177,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. State Street Corp grew its position in Annexon by 116.6% in the third quarter. State Street Corp now owns 3,841,879 shares of the company’s stock valued at $22,744,000 after acquiring an additional 2,068,294 shares during the last quarter. Sio Capital Management LLC acquired a new stake in shares of Annexon in the 3rd quarter valued at approximately $8,484,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Annexon by 221.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 732,216 shares of the company’s stock valued at $4,335,000 after purchasing an additional 504,656 shares during the last quarter. Geode Capital Management LLC increased its position in Annexon by 18.3% during the 3rd quarter. Geode Capital Management LLC now owns 2,143,635 shares of the company’s stock worth $12,693,000 after purchasing an additional 331,269 shares in the last quarter. Finally, Walleye Capital LLC acquired a new position in Annexon during the 3rd quarter worth approximately $1,946,000.

Annexon Trading Up 11.7 %

NASDAQ ANNX opened at $2.76 on Thursday. The firm has a market capitalization of $294.20 million, a PE ratio of -2.63 and a beta of 1.14. The business’s 50-day moving average price is $3.90 and its two-hundred day moving average price is $5.39. Annexon, Inc. has a 12 month low of $2.30 and a 12 month high of $8.40.

Annexon (NASDAQ:ANNX) last announced its earnings results on Monday, March 3rd. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.05). As a group, analysts forecast that Annexon, Inc. will post -0.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ANNX shares. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a research report on Friday, November 15th. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Annexon in a report on Tuesday, December 17th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 target price on shares of Annexon in a report on Tuesday. Six analysts have rated the stock with a buy rating, According to MarketBeat, Annexon presently has a consensus rating of “Buy” and an average price target of $15.80.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.